Concepedia
Statistics
Publications
4
Citations
115
H-Index
Active since
2013
Affiliations
AstraZeneca (United Kingdom)(Current)
Altimmune (United States)
Sanjoo Jalla is an author at AstraZeneca (United Kingdom) specializing in molecular oncology, oncology, and pharmacology.
Publications per year
2013–2017
Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody–Drug Conjugate Targeting 5T4
Jay Harper, Christopher Lloyd, Nazzareno Dimasi et al. · Molecular Cancer Therapeutics · 2017 · 47 citations · Full text
Pharmacy, Oncology, Pharmacology +17
Effective combination therapies in preclinical endocrine resistant breast cancer models harboring ER mutations
Brendon Ladd, Anne Marie Mazzola, Teeru Bihani et al. · Oncotarget · 2016 · 29 citations · Full text
Medicine, Oncology, Pharmacology +17
Novel Neutralizing Hedgehog Antibody MEDI-5304 Exhibits Antitumor Activity by Inhibiting Paracrine Hedgehog Signaling
Neil R. Michaud, Youzhen Wang, Kristen McEachern et al. · Molecular Cancer Therapeutics · 2013 · 22 citations · Full text
In Vivo Loss of Function Screening Reveals Carbonic Anhydrase IX as a Key Modulator of Tumor Initiating Potential in Primary Pancreatic Tumors
Nabendu Pore, Sanjoo Jalla, Zheng Liu et al. · Neoplasia · 2015 · 17 citations · Full text
Medicine, Molecular Biology, Oncology +16
1–4 of 4